Log in to search using one of your social media accounts:


Medical News Today: Pemphigus foliaceus: Symptoms, diagnosis, and treatment
In this article, learn about pemphigus foliaceus. What is pemphigus foliaceus, what causes pemphigus foliaceus and how is it diagnosed? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 31, 2017 Category: Consumer Health News Tags: Dermatology Source Type: news

FDA grants breakthrough therapy designation for MabThera/Rituxan (rituximab) in pemphigus vulgaris
Roche announced today that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation status to MabThera/Rituxan ® (rituximab) for pemphigus vulgaris, a rare, serious and life-threatening condition characterised by progressive painful blistering of the skin and mucous membranes. (Source: Roche Investor Update)
Source: Roche Investor Update - March 24, 2017 Category: Pharmaceuticals Source Type: news

Siteless: The Future of Clinical Trials?
This article is extracted fromTrends in Clinical Data& Technology. To download the magazine, clickhere.Related Content: The Patient Data Gold RushMeeting the Information Needs of PatientsTurning Clinical Trial Recruitment on its HeadConnecting with Patients via Compelling ContentPrimary Event: Data Quality and Technology in Clinical Trials USAPr écis: Clinical trials are moving out of the clinic and into patients ’ own homes.Premium`: Freemium`: Channels: ClinicalTags: Clinical DataClinical DevelopmentClinical Trial RecruitmentClinical Trial SoftwareClinical TrialsChannel...
Source: EyeForPharma - November 17, 2016 Category: Pharmaceuticals Authors: Danielle Barron Source Type: news

Cut-off Values in ABSIS and PDAI Pemphigus Scoring Systems Cut-off Values in ABSIS and PDAI Pemphigus Scoring Systems
The authors propose cut-off values which can be used to define moderate, significant and extensive pemphigus based on two new scoring systems intended to quantify the extent of disease.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 5, 2016 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Approach targets autoimmunity
Researchers developed a strategy to treat a rare autoimmune disease called pemphigus vulgaris and demonstrated its potential in a mouse model. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - July 25, 2016 Category: Consumer Health News Source Type: news

[Report] Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease
Ideally, therapy for autoimmune diseases should eliminate pathogenic autoimmune cells while sparing protective immunity, but feasible strategies for such an approach have been elusive. Here, we show that in the antibody-mediated autoimmune disease pemphigus vulgaris (PV), autoantigen-based chimeric immunoreceptors can direct T cells to kill autoreactive B lymphocytes through the specificity of the B cell receptor (BCR). We engineered human T cells to express a chimeric autoantibody receptor (CAAR), consisting of the PV autoantigen, desmoglein (Dsg) 3, fused to CD137-CD3ζ signaling domains. Dsg3 CAAR-T cells exhibit sp...
Source: ScienceNOW - July 7, 2016 Category: Science Authors: Christoph T. Ellebrecht Source Type: news

[In Depth] Fighting autoimmunity with immune cells
Autoimmune diseases share a grim similarity with cancer: People's own cells become their enemies. But a study published online in Science reveals a happier parallel, suggesting that a therapy designed to harness the immune system to attack cancer cells may also cull the turncoat immune cells behind certain autoimmune diseases. The approach relies on chimeric antigen receptor T cells, or CAR T cells: immune cells genetically modified to home in on a desired target on cancer cells or—in this case—on rogue B cells, another immune cell type. The new study only gauged the CAR T cells' capabilities in the lab dish an...
Source: ScienceNOW - June 30, 2016 Category: Science Authors: Mitch Leslie Tags: Immunology Source Type: news

Treating autoimmune disease without harming normal immunity
With potentially major implications for the future treatment of autoimmunity and related conditions, scientists have found a way to remove the subset of antibody-making cells that cause an autoimmune disease, without harming the rest of the immune system. They studied an autoimmune disease called pemphigus vulgaris, a condition in which a patient's own immune cells attack a protein called desmoglein-3 that normally adheres skin cells. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 30, 2016 Category: Science Source Type: news

What Causes Bullae?
Discussion Bullae are fluid-filled epidermal lesions that are filled with serous or seropurulent fluid. They are> 1 cm in diameter and often easily rupture due to their thin walls. The differential diagnosis is different for bullae than for vesicular lesions with bullae being often more worrisome. However there is overlap and vesicular diseases can become large enough to be bullae. Drug toxicity and genetic problems are also more common in bullae whereas vesicles are more often caused by infectious diseases. Potentially life threatening conditions such as toxic epidermal necrolysis syndrome, Stevens Johnson syndrome or...
Source: PediatricEducation.org - April 20, 2015 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

GSK’s Stiefel begins subcutaneous ofatumumab Phase III trial for pemphigus vulgaris
British drug maker GlaxoSmithKline’s (GSK) subsidiary Stiefel has commenced Phase III trial to assess the efficacy and safety of subcutaneous ofatumumab in patients with a rare autoimmune skin disorder, pemphigus vulgaris. (Source: Drug Development Technology)
Source: Drug Development Technology - October 7, 2014 Category: Pharmaceuticals Source Type: news

How skin falls apart: Pathology of autoimmune skin disease revealed at the nanoscale
Researchers studying a rare, blistering disease have discovered new details of how autoantibodies destroy healthy cells in skin. The research has the potential to help clinicians identify who may be at risk for developing Pemphigus vulgaris (PV), an autoimmune skin disorder, by distinguishing pathogenic (disease-causing) autoimmune antibodies from other nonpathogenic autoimmune antibodies. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 10, 2014 Category: Science Source Type: news

Stephen I. Katz
DirectorStephen I. Katz, M.D., Ph.D. has been Director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases since August 1995 and is also a Senior Investigator in the Dermatology Branch of the National Cancer Institute. He was born in New York in 1941 and his early years were spent in the Washington, D.C., and Bethesda, Maryland areas. After attending the University of Maryland, where he graduated with honors, he graduated from the Tulane University Medical School with honors in 1966. He completed a medical internship at Los Angeles County Hospital and did his dermatology residency at the University...
Source: PHRMA - July 30, 2014 Category: Pharmaceuticals Authors: Emily Source Type: news

Fixed-Dose Rituximab Provides Durable Remission of PemphigusFixed-Dose Rituximab Provides Durable Remission of Pemphigus
Fixed-dose rituximab therapy can produce durable remission of pemphigus, a retrospective study suggests. Reuters Health Information (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 13, 2014 Category: Dermatology Tags: Dermatology News Source Type: news

GSK begins Phase III study of subcutaneous Ofatumumab to treat pemphigus vulgaris
Genmab collaborator GlaxoSmithKline (GSK) has commenced the third phase of its study of subcutaneous formulation of ofatumumab, a human monoclonal antibody, to treat an autoimmune skin disorder, pemphigus vulgaris. (Source: Drug Development Technology)
Source: Drug Development Technology - July 4, 2013 Category: Pharmaceuticals Source Type: news

Genetics Home Reference: benign chronic pemphigus
New topic on Genetics Home Reference (Source: NLM General Announcements)
Source: NLM General Announcements - May 30, 2013 Category: Databases & Libraries Source Type: news

Rituximab may provide functional cure for pemphigus
Rituximab can induce long-term complete remission in patients with the chronic autoimmune disease pemphigus, show study findings. (Source: MedWire News - Dermatology)
Source: MedWire News - Dermatology - March 11, 2013 Category: Dermatology Source Type: news

In Mouse Model, Small Peptide Ameliorates Autoimmune Skin Blistering Disease
Pemphigus vulgaris is a life-threatening autoimmune skin disease that is occurs when the body's immune system generates antibodies that target proteins in the skin known as desomogleins. Desmogleins help to form the adhesive bonds that hold skin cells together and keep the skin intact. Currently, pemphigus vulgaris is treated by long-term immune suppression; however, this can leave the patient susceptible to infection... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 10, 2013 Category: Consumer Health News Tags: Immune System / Vaccines Source Type: news

In Vitro Pathogenicity Assay for Anti-desmoglein Autoantibodies in Pemphigus
We describe here two assays that measure the pathogenic strength of autoantibodies in blister formation: an in vitro dissociation assay using primary human epidermal keratinocytes to assess pathogenicity of anti-Dsg3 autoantibodies, and an alternative method whereby anti-Dsg3 and Dsg1 autoantibodies are injected into organ-cultured human skin specimen. (Source: Springer protocols feed by Molecular Medicine)
Source: Springer protocols feed by Molecular Medicine - December 19, 2012 Category: Molecular Biology Source Type: news